BRAF and melanoma: Since targeting BRAF in melanoma patients proved unsuccessful in the long term, the combined use of BRAF inhibitors with other therapeutic strategies (i.e., immunotherapy, standard chemotherapy or BH3-mimetics) is currently being studied.